Quanterix Corp

Quanterix Corp is a life sciences company that transforms healthcare innovation by accelerating biomarker breakthroughs from discovery to diagnostics. The company uses ultra-sensitive translational research and spatial biology instruments, consumables, and services. Quanterix focuses on shifting healthcare towards earlier detection, monitoring, prognosis, and prevention. Its combined platforms have an installed base of over 2,500 instruments and have been cited in more than 6,200 scientific publications, covering areas such as neurology, oncology, immunology, and inflammation. The company's proprietary digital "Simoa" detection technology allows customers to reliably detect protein biomarkers at ultra-low concentrations in blood, serum, and other fluids, often undetectable by conventional analog immunoassay technologies. Its "Spatial Biology" platforms enable multi-plexing biomarker analysis in tissue samples, helping scientists understand localized cellular interactions. The Simoa platforms can detect proteins in the femtomolar range, aiding in the development of novel therapies and diagnostics and potentially identifying early-stage disease markers. Quanterix sells its proprietary instruments and related consumables worldwide to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies. Additionally, the company provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. This laboratory, located in Bedford, Massachusetts, is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA).